Close to the edge: Neutralizing the HIV-1 envelope

Science

Volumn 308, Issue 5730, 2005, Pages 1878-1879

  Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE; AUTOANTIGEN; CARDIOLIPIN; EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

MEDICINE;

ANTIBODY PRODUCTION; DRUG SCREENING; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; GENETICS; HUMAN; IMMUNOLOGY; MUTATION; NOTE; PASSIVE IMMUNIZATION; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; AUTOANTIGENS; AUTOIMMUNE DISEASES; CARDIOLIPINS; COMPLEMENTARITY DETERMINING REGIONS; EPITOPES; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; HYDROPHOBICITY; IMMUNIZATION, PASSIVE; MODELS, MOLECULAR; MUTATION; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY;

EID: 21744447837     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1114854     Document Type: Review

References (20)

1. B. F. Haynes et al., Science 308, 1906 (2005); published online 28 April 2005 (10.1126/science.1111781).
2. A. Trkola et al., Nat Med. 10.1038/nm1244 (8 May 2005).
3. J. M. Binley et al., J. Virol. 78, 13232 (2004).
4. G. Ofek et al., J. Virol. 78, 10724 (2004).
5. M. B. Zwick et al., J. Virol., 79, 1252, (2004).
6. R. M. Cardoso et al., Immunity 22, 163 (2005).
7. Y. Louzoun et al., Bull. Math. Biol. 65, 535 (2003).
8. D. Nemazee, Immunol. Today 17, 25 (1996).
9. H. Wardemann et al., Science 301, 1374 (2003).
10. D. Gay et al., J. Exp. Med. 177, 999 (1993).
11. S. L. Tiegs, D. M. Russell, D. Nemazee, J. Exp. Med. 177, 1009 (1993).
12. D. A. Nemazee, K. Burki, Nature 337, 562 (1989).
13. E. Meffre et al., J. Clin. Invest. 108, 879 (2001).
14. F. M. Raaphorst, C. S. Raman, J. Tami, M. Fischbach, I. Sam, Int. Immunol. 9, 1503 (1997).
15. E. Meffre et al., Nat. Immunol. 1, 207 (2000).
16. R. A. Fox, D. A. Isenberg, Arthritis Rheum. 40, 1168 (1997).
17. R. Palacios, J. Santos, Int. J. STD AIDS 15, 277 (2004).
18. R. T. Canoso, L. I. Zon, J. E. Groopman, Br. J. Haematol. 65, 495 (1987).
19. M. B. Zwick et al., Nat. Med. 10, 133 (2004).
20. I thank P. Kwong and R. Wyatt for discussions and for use of graphic representations of Env and 2F5 structures; J. Mascola, R. Koup, and other VRC scientists for comments; and A. Tislerics, T. Miller, and B. Hartman for preparation of the manuscript.